

# Is Gem-Doce an alternative to BCG treatment for people with early bladder cancer?

<b>Submission date</b> 22/07/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/07/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 31/07/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The COBRA study is looking at a new treatment called Gem-Doce for people with early bladder cancer. The usual treatment, called BCG, has been used for over 40 years but often causes unpleasant side effects like bladder pain and flu-like symptoms. Many people don't finish the full course of BCG, and for some, the cancer still comes back or gets worse. The study aims to find out if Gem-Doce works just as well as BCG at stopping bladder cancer from returning, but with fewer side effects. It will also look at how the treatments affect people's quality of life and the cost of each option.

### Who can participate?

Patients aged 18 years and over across the UK who have recently been diagnosed with early bladder cancer and would normally be treated with BCG may be invited to take part

### What does the study involve?

People who join the study will be randomly given either BCG or Gem-Doce treatment. Both treatments are given directly into the bladder during hospital visits over 2 years. Everyone will have regular check-ups for five years, just like they would if they weren't in the study. Participants may also be asked to fill in optional questionnaires about their quality of life and healthcare use. These include questions about how they're feeling and how the treatment affects their daily life. There's also a short survey about background information, which is optional and confidential.

### What are the possible benefits and risks of participating?

Taking part could help researchers find a better treatment for bladder cancer in the future. Gem-Doce may cause fewer side effects than BCG, but both treatments can still cause discomfort, such as pain when passing urine or flu-like symptoms. Severe side effects are rare, and all participants will be fully informed before deciding whether to take part. People in the Gem-Doce group will have seven more treatment visits than those receiving BCG, but travel costs for these extra visits will be reimbursed.

### Where is the study run from?

The Institute of Cancer Research (UK)

When is the study starting and how long is it expected to run for?  
July 2025 to January 2032

Who is funding the study?  
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?  
cobra-icrctsu@icr.ac.uk

Plain English summary under review with external organisation

## Contact information

### Type(s)

Public, Scientific

### Contact name

Mr Steven Penegar

### Contact details

The Institute of Cancer Research  
15 Cotswold Road  
Sutton  
United Kingdom  
SM2 5NG  
+44 20 87224238  
cobra-icrctsu@icr.ac.uk

### Type(s)

Principal investigator

### Contact name

Prof Rakesh Heer

### Contact details

Fulham Palace Road  
London  
United Kingdom  
W6 8RF  
-  
cobra-icrctsu@icr.ac.uk

## Additional identifiers

Integrated Research Application System (IRAS)  
1008661

Central Portfolio Management System (CPMS)  
57987

## Protocol serial number

ICR-CTSU/2024/10091

# Study information

## Scientific Title

Combination chemotherapy versus Bacillus Calmette-Guérin (BCG) for high-risk non-muscle invasive bladder cancer– a phase III multi-centre randomised controlled trial (COBRA)

## Acronym

COBRA

## Study objectives

The main objective of the COBRA trial is to investigate whether Gem-Doce treatment, put into the bladder, has similar treatment success rates to the standard treatment, BCG. We will assess whether it is similar at preventing disease returning, which has a high risk of progressing into more advanced cancer, which is life-threatening.

### Secondary objectives:

1. To investigate whether Gem-Doce has similar rates as BCG in: any return or progression of bladder cancer after treatment, need for surgical removal of the bladder (cystectomy), death from cancer or any cause.
2. To compare side effects and the ability to complete a full course of each treatment
3. To investigate health-related quality of life as reported by participants.
4. To investigate the costs to the NHS and the cost-effectiveness of Gem-Doce treatment in comparison to BCG.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

notYetSubmitted, ref: 25/SC/0262

## Study design

Interventional randomized parallel-group controlled trial

## Primary study design

Interventional

## Study type(s)

Safety, Efficacy

## Health condition(s) or problem(s) studied

High-risk non-muscle invasive bladder cancer

## Interventions

Patients will receive up to four treatments in different sequences. Randomisation process: Sequential randomisation by computer-generated random permuted blocks.

### Treatment 1: BCG bladder instillations

Methodology: Intravesical BCG instillations

Generic drug name: Bacillus Calmette-Guérin

The dosage given: BCG (50 mg in 50 ml sodium chloride 0.9%)

Method of administration: Intravesical delivery

Frequency of administration: Six once-weekly induction intravesical instillations. Maintenance therapy delivered in three once-weekly instillations at months 3, 6, 12, 18 and 24 (15 instillations) until 24 months from the start of induction treatment

Total duration of treatment: 24 months

### Treatment 2: Gem-Doce bladder instillations

Methodology: Sequential intravesical gemcitabine and docetaxel instillations

Generic drug name: Gemcitabine and docetaxel

The dosage given: Gemcitabine (1 g in 50 ml sodium chloride 0.9%) and Docetaxel (40 mg in 50 ml sodium chloride 0.9%)

Method of administration: Intravesical delivery

Frequency of administration: Six once-weekly induction intravesical instillations. Maintenance therapy delivered once-monthly from months 3 - 24 (22 instillations) until 24 months from the start of induction treatment

Total duration of treatment: 24 months

Follow-up: Clinical follow-up to 2 years post-treatment will inform the primary analysis. Thereafter, all participants will be followed up according to NICE guidelines.

## Intervention Type

Drug

## Phase

Phase III

## Drug/device/biological/vaccine name(s)

Bacillus Calmette-Guérin, gemcitabine, docetaxel

## Primary outcome(s)

High-grade recurrence-free survival (hgRFS), i.e. time to first identification of high-grade recurrent disease, stage progression, metastatic disease or death from any cause. The primary analysis of hgRFS is planned to take place once the target number of events has been observed, expected when participants have at least 2 years of follow-up and have completed study treatment.

Persistent/recurrent HG pT1 or HG Ta papillary bladder cancer following induction therapy or persistent carcinoma in situ at 6 months will be considered high-grade recurrence events. The development of nodal disease or distant metastatic disease (based on cross-sectional imaging or histological confirmation - where biopsy is done, histology results will supersede imaging) is considered a high-grade recurrence event.

## Key secondary outcome(s)

1. Recurrence-free survival, defined in whole days as the time from the date of randomisation to the date of confirmed recurrence of non-muscle invasive bladder cancer (includes all events described in the primary endpoint, as well as recurrences of any grade); analysis after approximately 2 years follow-up (at the time of the primary endpoint).

2. Progression-free survival, defined in whole days as the time from the date of randomisation to the date of confirmed progression to muscle-invasive bladder cancer, nodal disease, distant metastatic disease, or death from any cause; analysis after approximately 2 years of follow-up (at the time of the primary endpoint)
3. Cystectomy-free survival, defined in whole days as the time from the date of randomisation to the date of cystectomy; analysis after approximately 2 years of follow-up (at the time of the primary endpoint)
4. Cancer-specific survival, defined in whole days as the time from the date of randomisation to the date of death specifically from bladder cancer; analysis after approximately 2 years of follow-up (at the time of the primary endpoint)
5. Overall survival, defined in whole days as the time from the date of randomisation to the date of death; for those who have not been reported as dead at the time of analysis; analysis after approximately 2 years of follow-up (at the time of the primary endpoint)
6. Complete response rate at 6 months (in patients with carcinoma in situ at baseline only), measured as the number of patients with an absence of cancer at 6-month cystoscopy (in patients with carcinoma in situ at baseline only)
7. Number of instillations received, measured over the 24-month induction and maintenance visit schedule of allocated treatment
8. Clinician assessed adverse events, measured by clinician-reported symptoms using CTCAE v5 over the 24-month induction and maintenance visit schedule
9. Patient-reported outcomes: health-related quality of life with an emphasis on overall quality of life, physical functioning, urinary symptoms and intravesical treatment issues, measured over the 24-month maintenance visit follow-up period, measured by the generic EORTC QLQ-F17, disease-specific QLQ-NMIBC24 and the generic EQ-5D-5L validated instruments
10. Costs to the NHS and personal social services, measured over the 24-month maintenance visit follow-up period and extrapolated over the patient lifetime
11. Incremental cost per quality-adjusted life year gained, measured over the 24-month maintenance visit follow-up period and extrapolated over the patient lifetime from responses to the EQ-5D-5L, cross-walked from responses to the EORTC QLQ-F17 as a sensitivity analysis

Unless advised otherwise by the IDMC, secondary endpoints will be reported at the time of the primary analysis.

### **Completion date**

31/01/2032

## **Eligibility**

### **Key inclusion criteria**

1. Written informed consent prior to any study-specific procedures
2. Age  $\geq 18$  years
3. WHO performance status 0-3
4. A new diagnosis of high-risk urothelial NMIBC with no variant histology:
  - 4.1. pT1 G2-3/high grade tumour (with or without CIS) OR
  - 4.2. pTa G3/high grade tumours (with or without CIS) OR
  - 4.3. Isolated carcinoma in situ (CIS)
5. Complete papillary tumour removal (apart from residual CIS) via TURBT
6. All patients with pT1 at initial TURBT should have had re-TURBT if there was no muscle in initial TURBT specimens. Re-resection should also be considered for patients with HG Ta if no muscle was present or for patients with HG T1 with muscle present at initial TURBT, according to local practice

7. Willing to use an effective method of contraception
8. Willing and able to comply with the follow-up schedule

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Any previous history of urothelial cancer
2. History of pure non-urothelial cell bladder cancer (adenocarcinoma, squamous cell carcinoma)
3. Evidence of neuroendocrine (small/ large cell) sarcomatoid, micropapillary or plasmacytoid variant urothelial cell cancer
4. Any urethral involvement
5. Any medical condition that contraindicates study treatment, including any known allergy to gemcitabine, docetaxel or BCG
6. Known pregnancy and/or currently breastfeeding
7. Known HIV, Hepatitis B or C with detectable viral load within 30 days prior to randomisation
8. Ongoing immunosuppressive medication, including steroids (>10 mg/day) - people receiving short courses (two weeks maximum) of steroids due to be discontinued prior to randomisation or using inhaled and topical steroids are eligible for randomisation
9. Active or treated malignancy within 1 year of randomisation (not including non-melanomatous skin carcinoma, NICE low-risk prostate cancer (T1/T2a, Gleason 6 PSA <10), in situ carcinoma of any site)

**Date of first enrolment**

01/08/2025

**Date of final enrolment**

31/07/2029

**Locations****Countries of recruitment**

United Kingdom

**Study participating centre**

**Not provided at time of registration**

United Kingdom

-

## Sponsor information

### Organisation

Institute of Cancer Research

### ROR

<https://ror.org/043jzw605>

## Funder(s)

### Funder type

Government

### Funder Name

Health Technology Assessment Programme

### Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from [cobra-icrctsu@icr.ac.uk](mailto:cobra-icrctsu@icr.ac.uk)

### IPD sharing plan summary

Available on request

### Study outputs

<b>Output type</b>	<b>Details</b>	<b>Date created</b>	<b>Date added</b>	<b>Peer reviewed?</b>	<b>Patient-facing?</b>
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes